Allen-Brady K, Verrilli L E, Austin B A, Letourneau J M, Johnstone E B, Welt C K
Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.
Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Utah School of Medicine, Salt Lake City, UT, USA.
Hum Reprod. 2025 Feb 1;40(2):391-396. doi: 10.1093/humrep/deae266.
Is there an increased risk of reproductive or colon cancer in women with Turner syndrome and their family members?
Our data suggest that there is an increased risk for sigmoid colon cancer in women with Turner syndrome and an increased prostate cancer risk in second- and third-degree male relatives.
Turner syndrome has been associated with lower risk of breast cancer, but increased risk of gonadoblastoma and colon cancer in some, but not all studies. There is also evidence for a genetic predisposition to sex chromosome aneuploidy, which may indicate a predisposition to Turner syndrome and the associated cancer risk in family members.
STUDY DESIGN, SIZE, DURATION: The study was a retrospective case-control study of women with Turner syndrome diagnosed from 1995 to 2021, their relatives, and population subjects from Utah.
PARTICIPANTS/MATERIALS, SETTING, METHODS: Women with Turner syndrome were identified using International Classification of Disease (ICD) codes in electronic medical records from two major Utah healthcare systems and reviewed for accuracy. Women with Turner syndrome were linked to genealogy in the Utah Population Database. Cancer diagnoses (breast, ovarian, endometrial, colon, testicular, and prostate) were determined for women with Turner syndrome and their relatives using the Utah Cancer Registry. Live births to women with Turner syndrome were identified by linked birth certificates. The relative risk of cancer in women with Turner syndrome and in relatives was estimated by comparison to population rates matched by age, sex, and birthplace.
We identified 289 women with Turner syndrome. Sigmoid colon cancer was increased in women with Turner syndrome (OR [95% CI] 24.2 [2.9, 87.4]; P = 0.0032). There were 233 women with Turner syndrome who had at least three generations of genealogical data. There was an increased risk of Turner syndrome in first- (OR [95% CI] 18.08 [2.19, 65.32]; P = 0.0057) and second-degree relatives (9.62 [1.17, 34.74]; P = 0.019), although numbers were very small. There was an increased risk of prostate cancer in second- (1.8 [1.4, 2.2]; P < 0.001) and third-degree relatives (1.3 [1.1, 1.5]; P < 0.001). There was no increased risk of colon cancer in relatives.
LIMITATIONS, REASONS FOR CAUTION: Based on the small number of sigmoid colon cancer cases, it is possible that our data have overestimated the colon cancer risk. Limitations include the identification of Turner syndrome by a diagnosis code in one of the two major health systems in Utah. The population is largely northern European with 9.3% of the women self-identified as Hispanic and 2.4% as Native American or multiple races. The results may not be generalizable to other populations.
Our data suggest that women with Turner syndrome may need early screening for colon cancer. Additional studies are needed to identify risk factors for sex chromosome aneuploidy and cancer risk in women with Turner syndrome and their male relatives.
STUDY FUNDING/COMPETING INTEREST(S): The work in this publication was supported by R56HD090159 and R01HD099487 (C.K.W.). We also acknowledge partial support for the Utah Population Database through grant P30 CA2014 from the National Cancer Institute. The Utah Cancer Registry is funded by the National Cancer Institute's SEER Program, Contract No. HHSN261201800016I, the US Centers for Disease Control and Prevention's National Program of Cancer Registries, Cooperative Agreement No. NU58DP007131, with additional support from the University of Utah and Huntsman Cancer Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors have no conflicts of interest.
N/A.
患有特纳综合征的女性及其家庭成员患生殖系统癌症或结肠癌的风险是否增加?
我们的数据表明,患有特纳综合征的女性患乙状结肠癌的风险增加,二级和三级男性亲属患前列腺癌的风险增加。
特纳综合征与较低的乳腺癌风险相关,但在一些(并非所有)研究中,患性腺母细胞瘤和结肠癌的风险增加。也有证据表明存在性染色体非整倍体的遗传易感性,这可能表明家庭成员中存在患特纳综合征及相关癌症风险的易感性。
研究设计、规模、持续时间:该研究是一项对1995年至2021年诊断出的患有特纳综合征的女性、她们的亲属以及来自犹他州的人群对象进行的回顾性病例对照研究。
参与者/材料、设置、方法:利用犹他州两个主要医疗系统电子病历中的国际疾病分类(ICD)编码识别出患有特纳综合征的女性,并对其准确性进行审查。患有特纳综合征的女性与犹他州人口数据库中的家谱相链接。利用犹他州癌症登记处确定患有特纳综合征的女性及其亲属的癌症诊断情况(乳腺癌、卵巢癌、子宫内膜癌、结肠癌、睾丸癌和前列腺癌)。通过链接的出生证明确定患有特纳综合征的女性的活产情况。通过与按年龄、性别和出生地匹配的人群发病率进行比较,估计患有特纳综合征的女性及其亲属患癌症的相对风险。
我们识别出289名患有特纳综合征的女性。患有特纳综合征的女性患乙状结肠癌的风险增加(比值比[95%置信区间]24.2[2.9, 87.4];P = 0.0032)。有233名患有特纳综合征的女性至少有三代家谱数据。一级亲属(比值比[95%置信区间]18.08[2.19, 65.32];P = 0.0057)和二级亲属(9.62[1.17, 34.74];P = 0.019)患特纳综合征的风险增加,尽管数量非常少。二级亲属(1.8[1.4, 2.2];P < 0.001)和三级亲属(1.3[1.1, 1.5];P < 0.001)患前列腺癌的风险增加。亲属患结肠癌的风险没有增加。
局限性、需谨慎的原因:基于乙状结肠癌病例数量较少,我们的数据有可能高估了结肠癌风险。局限性包括通过犹他州两个主要医疗系统之一中的诊断编码来识别特纳综合征。该人群主要是北欧人,9.3%的女性自我认定为西班牙裔,2.4%为美洲原住民或多种族。结果可能不适用于其他人群。
我们的数据表明,患有特纳综合征的女性可能需要早期筛查结肠癌。需要进一步研究以确定特纳综合征女性及其男性亲属中性染色体非整倍体和癌症风险的危险因素。
研究资金/利益冲突:本出版物中的工作得到了R56HD090159和R01HD099487(C.K.W.)的支持。我们还感谢通过美国国立癌症研究所的P30 CA2014赠款对犹他州人口数据库的部分支持。犹他州癌症登记处由美国国立癌症研究所的监测、流行病学和最终结果(SEER)计划资助,合同编号HHSN261201800016I,美国疾病控制与预防中心的国家癌症登记计划,合作协议编号NU58DP007131,并得到犹他大学和亨斯迈癌症基金会的额外支持。内容完全由作者负责,不一定代表美国国立卫生研究院的官方观点。作者没有利益冲突。
无。